(S1 (S (S (NP (NP (NP (NN RUNX1) (JJ DNA-binding) (NNS mutations)) (CC and) (NP (NN RUNX1-PRDM16) (JJ cryptic) (NNS fusions))) (PP (IN in) (NP (JJ BCR-ABL+) (NNS leukemias)))) (VP (VP (VBP are) (ADVP (RB frequently)) (VP (VBN associated) (PP (IN with) (NP (JJ secondary) (NN trisomy) (CD 21))))) (CC and) (VP (MD may) (VP (VB contribute) (PP (TO to) (NP (NP (JJ clonal) (NN evolution)) (CC and) (NP (NN imatinib) (NN resistance)))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Acquired) (JJ molecular) (NNS abnormalities)) (PRN (-LRB- -LRB-) (NP (NP (NNS mutations)) (CC or) (NP (JJ chromosomal) (NNS translocations))) (-RRB- -RRB-))) (PP (IN of) (NP (DT the) (NN RUNX1) (NN transcription) (NN factor) (NN gene)))) (VP (VBP are) (ADJP (JJ frequent) (PP (PP (IN in) (NP (NP (JJ acute) (JJ myeloblastic) (NNS leukemias)) (PRN (-LRB- -LRB-) (NP (NNS AMLs)) (-RRB- -RRB-)))) (CC and) (PP (IN in) (NP (JJ therapy-related) (JJ myelodysplastic) (NNS syndromes))) (, ,) (CC but) (ADVP (RB rarely)) (PP (IN in) (NP (NP (NP (JJ acute) (JJ lymphoblastic) (NNS leukemias)) (PRN (-LRB- -LRB-) (NP (NNS ALLs)) (-RRB- -RRB-))) (CC and) (NP (NP (JJ chronic) (JJ myelogenous) (NNS leukemias)) (PRN (-LRB- -LRB-) (NP (NN CMLs)) (-RRB- -RRB-))))))))) (. .)))
(S1 (S (PP (IN Among) (NP (NP (CD 18) (JJ BCR-ABL+) (NNS leukemias)) (VP (VBG presenting) (NP (NP (VBN acquired) (NN trisomy)) (PP (IN of) (NP (NN chromosome) (CD 21))))))) (, ,) (NP (PRP we)) (VP (VBP report) (NP (NP (NP (DT a) (JJ high) (NN frequency)) (PRN (-LRB- -LRB-) (NP (CD 33) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (NP (NP (JJ recurrent) (NN point) (NNS mutations)) (PRN (-LRB- -LRB-) (NP (NP (NP (CD 4)) (PP (IN in) (NP (NP (NP (JJ myeloid) (NN blast) (NN crisis)) (PRN (-LRB- -LSB-) (NP (NN BC)) (-RRB- -RSB-))) (NN CML)))) (CC and) (NP (NP (CD one)) (PP (IN in) (NP (JJ chronic) (NN phase) (NN CML))))) (-RRB- -RRB-))) (PP (IN within) (NP (NP (DT the) (JJ DNA-binding) (NN region)) (PP (IN of) (NP (NN RUNX1))))))))) (. .)))
(S1 (S (S (NP (PRP We)) (VP (VBD did) (RB not) (VP (VBN found) (NP (DT any) (NN mutation)) (PP (IN in) (NP (NP (ADJP (FW de) (FW novo)) (NN BCR-ABL+) (NN ALLs)) (CC or) (NP (JJ lymphoid) (NN BC) (NN CML))))))) (. .)))
(S1 (S (S (NP (NP (NN Emergence)) (PP (IN of) (NP (DT the) (NN RUNX1) (NNS mutations)))) (VP (VBD was) (VP (VBN detected) (PP (PP (IN at) (NP (NN diagnosis))) (CC or) (PP (IN before) (NP (NP (DT the) (NN acquisition)) (PP (IN of) (NP (NN trisomy) (CD 21))))) (PP (IN during) (NP (NN disease) (NN progression))))))) (. .)))
(S1 (S (PP (IN In) (NP (NN addition))) (, ,) (NP (PRP we)) (ADVP (RB also)) (VP (VBP report) (NP (NP (DT a) (JJ high) (NN frequency)) (PP (IN of) (NP (NP (JJ cryptic) (NN chromosomal) (NN RUNX1) (NN translocation)) (PP (TO to) (NP (NP (DT a) (JJ novel) (ADJP (RB recently) (VBN described)) (NN gene) (NN partner)) (, ,) (NP (NN PRDM16))))))) (PP (IN on) (NP (NN chromosome) (NN 1p36))) (, ,) (PP (PP (IN for) (NP (NP (NP (NP (CD 3)) (PRN (-LRB- -LRB-) (NP (CD 21.4) (NN %)) (-RRB- -RRB-))) (PP (IN of) (NP (CD 14) (VBN investigated) (NNS patients)))) (: :) (NP (CD 2) (JJ myeloid) (NN BC) (NN CMLs)))) (CC and) (, ,) (PP (IN for) (NP (NP (DT the) (JJ first) (NN time)) (, ,) (NP (CD 1) (JJ therapy-related) (JJ BCR-ABL+) (NN ALL)))))) (. .)))
(S1 (S (S (NP (CD Two) (NNS patients)) (VP (VBD presented) (NP (CC both) (NP (NN RUNX1) (NNS mutations)) (CC and) (NP (NN RUNX1-PRDM16) (NN fusion))))) (. .)))
(S1 (S (S (NP (DT These) (NNS events)) (VP (VP (VBP are) (VP (VBN associated) (PP (IN with) (NP (DT a) (JJ short) (NN survival))))) (CC and) (VP (VBP support) (NP (NP (DT the) (NN concept)) (PP (IN of) (NP (NP (DT a) (JJ cooperative) (NN effect)) (PP (IN of) (NP (NN BCR-ABL))) (PP (IN with) (NP (NP (JJ molecular) (NN RUNX1) (NNS abnormalities)) (PP (IN on) (NP (NP (NP (DT the) (NN differentiation) (NN arrest)) (NN phenotype)) (VP (VBN observed) (PP (PP (IN during) (NP (NP (NN progression)) (PP (IN of) (NP (NN CML))))) (CC and) (PP (IN in) (NP (JJ BCR-ABL+) (NN ALL))))))))))))))) (. .)))
